Eli Lilly (LLY) Q4 Earnings Beat, Mounjaro, Zepbound Drive Sales

Eli Lilly and Company (LLY) reported fourth-quarter 2023 adjusted earnings per share (“EPS”) of $2.49, which beat the Zacks Consensus Estimate of $2.46 per share. Earnings rose 19% year over year.Revenues of $9.35 billion beat the Zacks Consensus Estimate of $8.86 billion. Sales rose 28% year over year, driven by exceptionally strong demand for Lilly’s FDA-approved tirzepatide medicines, diabetes drug Mounjaro and newly launched weight loss medicine, Zepbound.Quarter in DetailIn the reported quarter, net re ...